Publication

Article

Oncology & Biotech News

January 2011
Volume5
Issue 1

Company Claims to Make Safer Smokeless Tobacco

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a

Star Scientific, a Virginia-based company, has petitioned the FDA to approve the sale of what it claims is a "safer" smokeless tobacco. Stonewall Moist-BDL is a tobacco lozenge that the manufacturer claims contains 90% to 99% less carcinogens than currently marketed smokeless tobacco products. Under the Family Smoking Prevention and Tobacco Control Act passed in 2009, the FDA is authorized to regulate tobacco products, and the company is hoping to receive the "modified risk" label that the FDA is working to develop. Like cigarettes, smokeless tobacco is addictive and considered harmful to human health.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.